pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

10,173 catalysts · 5,445 approval · 5,000 device 510k · 4,728 grant · 3,048 8k filing · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 19 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 17 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: approval×type: grant×from 2023-02-08×clear all
type
  • approval5,445
  • device 510k5,000
  • grant4,728
  • 8k filing3,048
  • device pma2,000
  • device recall2,000
recall
1,126
  • device adverse event1,000
  • earnings582
  • phase 2 completion172
  • therapy area

    no tagged catalysts yet

    Week of Feb 6, 2023

    15
    ›Feb 8, 2023approval1280d agoXARELTO (RIVAROXABAN) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Feb 8, 2023approval1280d agoXARELTO (RIVAROXABAN) — FDA approvalJanssen Therapeutics

    Sponsor: JANSSEN PHARMS. Form: FOR SUSPENSION. Route: ORAL

    full page →fda approvals ↗
    ›Feb 8, 2023approval1280d agoFENTANYL CITRATE — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: EXELA PHARMA. Form: SOLUTION. Route: INTRAVENOUS

    full page →fda approvals ↗
    ›Feb 8, 2023approval1280d agoBUPROPION HYDROCHLORIDE — FDA approvalInvaGen Pharmaceuticals Inc

    Sponsor: INVAGEN PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Feb 8, 2023approval1280d agoBUPROPION HYDROCHLORIDE — FDA approvalInvaGen Pharmaceuticals Inc

    Sponsor: INVAGEN PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Feb 9, 2023approval1279d agoRAMELTEON — FDA approvalRAMELTEON

    Sponsor: MICRO LABS. Form: TABLET. Route: ORAL

    full page →RAMELTEON →fda approvals ↗
    ›Feb 9, 2023approval1279d agoACETAZOLAMIDE — FDA approvalACETAZOLAMIDE

    Sponsor: MANKIND PHARMA. Form: TABLET. Route: ORAL

    full page →ACETAZOLAMIDE →fda approvals ↗
    ›Feb 9, 2023approval1279d agoOLANZAPINE — FDA approvalolanzapine ODT

    Sponsor: DR REDDYS LABS LTD. Form: TABLET. Route: ORAL

    full page →olanzapine ODT →fda approvals ↗
    ›Feb 10, 2023approval1278d agoEPIPEN E Z PEN (EPINEPHRINE) — FDA approvaladrenaline

    Sponsor: VIATRIS. Form: INJECTABLE. Route: INTRAMUSCULAR

    full page →adrenaline →fda approvals ↗
    ›Feb 10, 2023approval1278d agoOLANZAPINE — FDA approvalolanzapine ODT

    Sponsor: DR REDDYS LABS LTD. Form: TABLET. Route: ORAL

    full page →olanzapine ODT →fda approvals ↗
    ›Feb 10, 2023approval1278d agoRIFADIN (RIFAMPIN) — FDA approvalRIFADIN

    Sponsor: SANOFI AVENTIS US. Form: INJECTABLE. Route: INJECTION

    full page →RIFADIN →fda approvals ↗
    ›Feb 10, 2023approval1278d agoRIFATER (ISONIAZID) — FDA approvalRIFATER

    Sponsor: SANOFI AVENTIS US. Form: TABLET. Route: ORAL

    full page →RIFATER →fda approvals ↗
    ›Feb 10, 2023approval1278d agoRIFADIN (RIFAMPIN) — FDA approvalRIFADIN

    Sponsor: SANOFI AVENTIS US. Form: CAPSULE. Route: ORAL

    full page →RIFADIN →fda approvals ↗
    ›Feb 10, 2023approval1278d agoARIKAYCE KIT (AMIKACIN SULFATE) — FDA approvalamikacin sulfate PR

    Sponsor: INSMED INC. Form: SUSPENSION, LIPOSOMAL. Route: INHALATION

    full page →amikacin sulfate PR →fda approvals ↗
    ›Feb 10, 2023approval1278d agoOLANZAPINE — FDA approvalolanzapine ODT

    Sponsor: DR REDDYS LABS LTD. Form: TABLET, ORALLY DISINTEGRATING. Route: ORAL

    full page →olanzapine ODT →fda approvals ↗

    Week of Feb 13, 2023

    22
    ›Feb 13, 2023approval1275d agoCABOMETYX (CABOZANTINIB S-MALATE) — FDA approvalcabozantinib s-malate

    Sponsor: EXELIXIS INC. Form: TABLET. Route: ORAL

    full page →cabozantinib s-malate →fda approvals ↗
    ›Feb 14, 2023approval

    Week of Feb 20, 2023

    10
    ›Feb 21, 2023approval1267d agoPIROXICAM — FDA approvalNostrum Pharmaceuticals LLC

    Sponsor: UNICHEM. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Feb 21, 2023approval

    Week of Feb 27, 2023

    3
    ›Feb 27, 2023approval1261d agoCABENUVA KIT (CABOTEGRAVIR) — FDA approvalViiV Healthcare Company

    Sponsor: VIIV HLTHCARE. Form: SUSPENSION, EXTENDED RELEASE. Route: INTRAMUSCULAR

    full page →fda approvals ↗
    ›Feb 27, 2023approval
    ← prev
    page 1 of 204
    next →
    1274d ago
    WEGOVY (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Feb 15, 2023approval1273d agoOPDIVO (NIVOLUMAB) — FDA approvalnivolumab

    Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION

    full page →nivolumab →fda approvals ↗
    ›Feb 15, 2023approval1273d agoOPDIVO (NIVOLUMAB) — FDA approvalnivolumab

    Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION

    full page →nivolumab →fda approvals ↗
    ›Feb 15, 2023approval1273d agoOPDIVO (NIVOLUMAB) — FDA approvalnivolumab

    Sponsor: BRISTOL MYERS SQUIBB. Form: INJECTABLE. Route: INJECTION

    full page →nivolumab →fda approvals ↗
    ›Feb 15, 2023approval1273d agoIBANDRONATE SODIUM — FDA approvalDR REDDYS LABORATORIES LTD

    Sponsor: ORBION PHARMS. Form: TABLET. Route: ORAL

    full page →fda approvals ↗
    ›Feb 16, 2023approval1272d agoTOPIRAMATE — FDA approvaltopiramate ER

    Sponsor: GLENMARK PHARMS LTD. Form: TABLET. Route: ORAL

    full page →topiramate ER →fda approvals ↗
    ›Feb 16, 2023approval1272d agoTOPIRAMATE — FDA approvaltopiramate ER

    Sponsor: GLENMARK PHARMS LTD. Form: TABLET. Route: ORAL

    full page →topiramate ER →fda approvals ↗
    ›Feb 16, 2023approval1272d agoTOPIRAMATE — FDA approvaltopiramate ER

    Sponsor: GLENMARK PHARMS LTD. Form: TABLET. Route: ORAL

    full page →topiramate ER →fda approvals ↗
    ›Feb 16, 2023approval1272d agoTOPIRAMATE — FDA approvaltopiramate ER

    Sponsor: GLENMARK PHARMS LTD. Form: TABLET. Route: ORAL

    full page →topiramate ER →fda approvals ↗
    ›Feb 16, 2023approval1272d agoTOPIRAMATE — FDA approvaltopiramate ER

    Sponsor: GLENMARK PHARMS LTD. Form: TABLET. Route: ORAL

    full page →topiramate ER →fda approvals ↗
    ›Feb 16, 2023approval1272d agoTOPIRAMATE — FDA approvaltopiramate ER

    Sponsor: GLENMARK PHARMS LTD. Form: TABLET. Route: ORAL

    full page →topiramate ER →fda approvals ↗
    ›Feb 16, 2023approval1272d agoTOPIRAMATE — FDA approvaltopiramate ER

    Sponsor: GLENMARK PHARMS LTD. Form: TABLET. Route: ORAL

    full page →topiramate ER →fda approvals ↗
    ›Feb 16, 2023approval1272d agoTOPIRAMATE — FDA approvaltopiramate ER

    Sponsor: GLENMARK PHARMS LTD. Form: TABLET. Route: ORAL

    full page →topiramate ER →fda approvals ↗
    ›Feb 16, 2023approval1272d agoTOPIRAMATE — FDA approvaltopiramate ER

    Sponsor: GLENMARK PHARMS LTD. Form: TABLET. Route: ORAL

    full page →topiramate ER →fda approvals ↗
    ›Feb 16, 2023approval1272d agoTOPIRAMATE — FDA approvaltopiramate ER

    Sponsor: GLENMARK PHARMS LTD. Form: TABLET. Route: ORAL

    full page →topiramate ER →fda approvals ↗
    ›Feb 17, 2023approval1271d agoFILSPARI (SPARSENTAN) — FDA approvalsparsentan

    Sponsor: TRAVERE. Form: TABLET. Route: ORAL

    full page →sparsentan →fda approvals ↗
    ›Feb 17, 2023approval1271d agoSPINRAZA (NUSINERSEN SODIUM) — FDA approvalBIOGEN INC.

    Sponsor: BIOGEN IDEC. Form: SOLUTION. Route: INTRATHECAL

    full page →fda approvals ↗
    ›Feb 17, 2023approval1271d agoERLEADA (APALUTAMIDE) — FDA approvalapalutamide

    Sponsor: JANSSEN BIOTECH. Form: TABLET. Route: ORAL

    full page →apalutamide →fda approvals ↗
    ›Feb 17, 2023approval1271d agoLEQVIO (INCLISIRAN SODIUM) — FDA approvalinclisiran

    Sponsor: NOVARTIS. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →inclisiran →fda approvals ↗
    ›Feb 17, 2023approval1271d agoRIFADIN (RIFAMPIN) — FDA approvalRIFADIN

    Sponsor: SANOFI AVENTIS US. Form: INJECTABLE. Route: INJECTION

    full page →RIFADIN →fda approvals ↗
    ›Feb 17, 2023approval1271d agoRIFADIN (RIFAMPIN) — FDA approvalRIFADIN

    Sponsor: SANOFI AVENTIS US. Form: CAPSULE. Route: ORAL

    full page →RIFADIN →fda approvals ↗
    1267d ago
    PIROXICAM — FDA approvalNostrum Pharmaceuticals LLC

    Sponsor: UNICHEM. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Feb 23, 2023approval1265d agoIRBESARTAN AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalALDACTAZIDE

    Sponsor: PRINSTON INC. Form: TABLET. Route: ORAL

    full page →ALDACTAZIDE →fda approvals ↗
    ›Feb 23, 2023approval1265d agoIRBESARTAN AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalALDACTAZIDE

    Sponsor: PRINSTON INC. Form: TABLET. Route: ORAL

    full page →ALDACTAZIDE →fda approvals ↗
    ›Feb 23, 2023approval1265d agoIRBESARTAN AND HYDROCHLOROTHIAZIDE (HYDROCHLOROTHIAZIDE) — FDA approvalALDACTAZIDE

    Sponsor: PRINSTON INC. Form: TABLET. Route: ORAL

    full page →ALDACTAZIDE →fda approvals ↗
    ›Feb 23, 2023approval1265d agoLOSARTAN POTASSIUM — FDA approvalLOSARTAN POTASSIUM

    Sponsor: GRANULES. Form: TABLET. Route: ORAL

    full page →LOSARTAN POTASSIUM →fda approvals ↗
    ›Feb 24, 2023approval1264d agoDEPAKOTE (DIVALPROEX SODIUM) — FDA approvaldivalproex sodium DR

    Sponsor: ABBVIE. Form: CAPSULE, DELAYED REL PELLETS. Route: ORAL

    full page →divalproex sodium DR →fda approvals ↗
    ›Feb 24, 2023approval1264d agoDEPAKOTE ER (DIVALPROEX SODIUM) — FDA approvaldivalproex sodium DR

    Sponsor: ABBVIE. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →divalproex sodium DR →fda approvals ↗
    ›Feb 24, 2023approval1264d agoDEPAKOTE (DIVALPROEX SODIUM) — FDA approvaldivalproex sodium DR

    Sponsor: ABBVIE. Form: TABLET, DELAYED RELEASE. Route: ORAL

    full page →divalproex sodium DR →fda approvals ↗
    ›Feb 24, 2023approval1264d agoOLANZAPINE — FDA approvalolanzapine ODT

    Sponsor: CADILA PHARMS LTD. Form: TABLET. Route: ORAL

    full page →olanzapine ODT →fda approvals ↗
    1261d ago
    YUSIMRY (ADALIMUMAB-AQVH) — FDA approvalYUSIMRY

    Sponsor: COHERUS BIOSCIENCES INC. Form: INJECTABLE. Route: INJECTION

    full page →YUSIMRY →fda approvals ↗
    ›Feb 28, 2023approval1260d agoSKYCLARYS (OMAVELOXOLONE) — FDA approvalReata Pharmaceuticals Inc

    Sponsor: BIOGEN US. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    $RDY12.15-0.57%
    $INSM134.75+2.78%
    $RDY12.15-0.57%
    $VTRS16.28-0.91%
    $RDY12.15-0.57%
    $EXEL52.96-2.05%
    $BMY64.84+0.19%
    $RDY12.15-0.57%
    $BMY64.84+0.19%
    $TVTX60.89-0.70%
    $BMY64.84+0.19%
    $NVS156.79+0.29%
    $ABBV247.97+0.78%
    $BIIB207.13-0.39%
    $ABBV247.97+0.78%
    $ABBV247.97+0.78%
    $COGT41.53-2.03%